allergic conjunctivitis

(redirected from Allergic rhinoconjunctivitis)
Also found in: Wikipedia.

al·ler·gic con·junc·ti·vi·tis

an immunologic reaction of the conjunctivae mediated by immunoglobulin E that is associated with itching, redness, and tearing; it is typically seasonal, is brought about by allergy (rather than infection), may be associated with other stigmata of allergic reactions, and may affect up to 10% of the population.

allergic conjunctivitis

an inflammation of the conjunctiva caused by an allergy. Common allergens that cause this condition are pollen, grass, topical medications, air pollutants, occupational irritants, and smoke. This condition is bilateral, usually starts before puberty, and commonly recurs in a seasonal pattern. Also called redeye. See also conjunctivitis.
observations Common signs include itching, burning, and swelling around the eyes and excessive tearing. Eosinophils predominate in stained blood smears. The diagnosis is usually based on the results of cultures and sensitivity tests to identify the causative allergen.
interventions Oral antihistamines and vasoconstrictor and corticosteroid eyedrops, such as predniSONE are typically prescribed.
nursing considerations Cold compresses may be administered.

allergic conjunctivitis

Allergy-induced conjunctival inflammation, which may accompany hay fever.
 
Clinical findings
Itchy, red, tearing eyes.
 
Management
Topical cromolyn, vasoconstrictors, cold compresses, oral antihistamines, air-conditioning.

allergic conjunctivitis

Ophthalmology Allergy-induced conjunctival inflammation which may accompany hay fever Clinical Itchy, red, tearing eyes Management Topical cromolyn, vasoconstrictors, cold compresses, oral antihistamines, air-conditioning. See Hay fever.

al·ler·gic con·junc·ti·vi·tis

(ă-lĕr'jik kŏn-jŭngk'ti-vī'tis)
Acute conjunctivitis characterized by itching and watery discharge; typically with bilateral involvement.

al·ler·gic con·junc·ti·vi·tis

(ă-lĕr'jik kŏn-jŭngk'ti-vī'tis)
Immunologic conjunctival reaction mediated by immunoglobulin E; associated with itching, redness, and tearing.
References in periodicals archive ?
Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys.
Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis.
Bilastine is a H1 anti-histamine drug approved for the treatment of allergic rhinoconjunctivitis and urticaria in the European Union in 2010 and more recently in some other countries in Latin America.
ANTONY, France, October 27 /PRNewswire/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults.
The prevalence of symptoms of allergic rhinoconjunctivitis ranged between 15 and 25% among children 13-14 years of age who lived in the United States or the United Kingdom (International Study of Asthma and Allergies in Childhood 1998).
It is also highly effective in controlling ocular symptoms associated with allergic rhinoconjunctivitis.
The AGH study, "Sublingual Immunotherapy in Patients with Allergic Rhinoconjunctivitis Caused by Ragweed Pollen," involved 115 patients in Pittsburgh, Madison, Wisc.
Oralair(R) Grasses is a fast-dissolving tablet that has demonstrated high efficacy in treating allergic rhinoconjunctivitis to grass pollen starting with the first season, lasting throughout the pollen season, and at the pollen peak, on:
NEW ORLEANS -- In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo (p=0.
The Phase IIb trial follows the successful completion of a Phase IIa programme in which four Phase IIa trials were completed with efficacy demonstrated in asthma and allergic rhinoconjunctivitis.
ANTONY, France, October 27 /PRNewswire-FirstCall/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults.
Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen.